Suppr超能文献

2022 年至 2040 年中国酒精性肝病发病和死亡的预估:一项建模研究。

Estimated projection of incidence and mortality of alcohol-related liver disease in China from 2022 to 2040: a modeling study.

机构信息

Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.

Institute of Clinical Pharmacy, Central South University, Changsha, 410011, Hunan, China.

出版信息

BMC Med. 2023 Jul 27;21(1):277. doi: 10.1186/s12916-023-02984-7.

Abstract

BACKGROUND

China has one of the highest numbers of liver disease cases in the world, including 6.4 million cirrhosis associated with alcohol-related liver disease (ALD) cases. However, there is still a lack of urgent awareness about the growth of alcohol consumption and the increased burden of ALD in China. Therefore, we aimed to project the potential impact of changes in alcohol consumption on the burden of ALD in China up to 2040 under different scenarios.

METHODS

We developed a Markov model to simulate the natural history of ALD until 2040 in China. We estimated the incidence and mortality of alcohol-related cirrhosis and hepatocellular carcinoma between 2022 and 2040 under four projected scenarios: status quo scenario and scenarios with a 2%, 4%, and 8% annual decrease in excessive alcohol consumption, respectively.

RESULTS

Under the status quo scenario, the cumulative new cases of cirrhosis from 2022 to 2040 was projected to be 3.61 million (95% UI 3.03-4.44 million), resulting in a cumulative 1.96 million (1.66-2.32 million) deaths from alcohol-related cirrhosis and hepatocellular carcinoma. However, a 2% annual reduction in excessive alcohol consumption was expected to avert 0.3 million deaths associated with ALD, and a 4% annual reduction was projected to prevent about 1.36 million new cases of cirrhosis and prevent 0.5 million ALD-related deaths. Moreover, an 8% annual reduction would prevent about 2 million new cases of cirrhosis and 0.82 million deaths.

CONCLUSIONS

Without any substantial change in alcohol attitudes and policies to regulate excessive drinking, the disease burden of ALD in China will increase enormously. Strengthening the implementation of alcohol restriction interventions is critical and urgent to reduce the impact of ALD on the Chinese population.

摘要

背景

中国是世界上肝病病例最多的国家之一,包括 640 万例与酒精性肝病(ALD)相关的肝硬化病例。然而,人们对中国饮酒量的增长和 ALD 负担的增加仍然缺乏紧迫意识。因此,我们旨在根据不同情景预测饮酒量变化对中国 ALD 负担的潜在影响,直至 2040 年。

方法

我们开发了一个马尔可夫模型,以模拟中国 ALD 的自然病史,直至 2040 年。我们根据四个预测情景,即现状情景和过量饮酒量分别以每年 2%、4%和 8%的速度下降的情景,估计了 2022 年至 2040 年期间酒精性肝硬化和肝细胞癌的发病率和死亡率。

结果

在现状情景下,预计 2022 年至 2040 年期间,肝硬化的累计新发病例数为 361 万例(95%可信区间为 303-444 万例),累计有 196 万例(166-232 万例)因酒精性肝硬化和肝细胞癌而死亡。然而,每年减少 2%的过量饮酒预计可避免 30 万例与 ALD 相关的死亡,每年减少 4%预计可预防约 136 万例新的肝硬化病例,可预防 50 万例与 ALD 相关的死亡。此外,每年减少 8%可预防约 200 万例肝硬化新发病例和 82 万例死亡。

结论

如果不对饮酒态度和控制过度饮酒的政策进行实质性改变,中国的 ALD 疾病负担将大大增加。加强实施酒精限制干预措施对于减轻 ALD 对中国人口的影响至关重要且紧迫。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/56dc/10375628/1c5572688a73/12916_2023_2984_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验